Nabriva Corporate
Go to...
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us
  • News & Publications
  • Careers
  • Contact Us
Nabriva Corporate
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us

imprint

Home / imprint

Nabriva Therapeutics GMBH

Leberstrasse 20
1110 Vienna, Austria

T +43 (0)1 740 93-0

F +43 (0)1 740 93-1900

office@nabriva.com

Commercial Register File No. (Firmenbuchnummer): 269261 y

Competent Commercial Register Court (zuständiges Firmenbuchgericht): Commercial Court of Vienna, Marxergasse 1a, A-1030 Vienna

VAT Identification Number (UID-Number): ATU62319422

Competent Supervisory Authorities:

  • Vienna City Administration, Municipal Department 63 (Magistrat der Stadt Wien, MA63), Wipplingerstraße 8, A-1010 Vienna
  • Federal Office for Security in the Health Care Sector (Bundesamt für Sicherheit im Gesundheitswesen), Schnirchgasse 9, A-1030 Vienna

Competent Economic Chamber: Vienna Economic Chamber (Wirtschaftskammer Wien), www.wko.at

Applicable Business Regulations:

  • Austrian Business and Trade Code, Federal Law Gazette 1994/194, as amended by Federal Law Gazette I 2006/161 (Gewerbeordnung, BGBl 1994/194, idF BGBl I 2006/161);
  • Austrian Act on Pharmaceutical Products, Federal Law Gazette 1983/185, as amended by Federal Law Gazette I 153/2005 (Arzneimittelgesetz, BGBl 1983/185 idF BGBl I 153/2005);

accessible free of charge at www.ris.bka.gv.at

Nabriva Response to COVID-19

Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic.  Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics.  XenletaTM (lefamulin) may be an alternative regimen for patients in need.  Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors.  Learn more at www.XENLETA.com.

Again, to all the medical professionals, please be safe, take care of yourself and stay well.

Best,
Ted Schroeder
CEO, Nabriva Therapeutics

Continue to site

Nabriva logo
  • Privacy Notice
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland

  • Privacy Notice
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap
Nabriva logo

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland